Israeli versus US seed pricing: what the published data shows, and what it does not

The published numbers

Round size is easier to compare than valuation, and the labels mislead. US seed rounds had a median deal value of $3.0 million in H1 2026 per the PitchBook-NVCA Venture Monitor, down from $3.5 million in 2025. Tracked Israeli seed deals in the same half had a median of $10.1 million, or $8.0 million without the largest handful.

Round size is easier to compare than valuation, and the seed label means different things in each market.

IVC's quarterly review groups pre-Seed through Series A as "early rounds". It shows the Israeli median rising from $10.5 million in 2025 to $14 million in the first half of 2026, with a caveat: capital is concentrating in fewer companies. Fewer startups are raising, and the ones that do are raising more. At the other end, IVC's pre-Seed median has been flat at $0.2 million since 2023. On the US side, the same PitchBook report notes that seed is the only series whose median deal value fell in the first half of 2026, while median pre-money valuations at every series have pushed past their 2021 highs.

None of the sources this site relies on publish a seed pre-money valuation median for Israel. Carta reports US seed medians (its Q1 2026 summary cites a $24 million median post-money on a $4.1 million round), but the public IVC and Startup Nation Central reports have no Israeli equivalent. The data note tracks both series and shows them as pending until a sourced figure exists.

Why the gap exists

The round-size gap exists because Israeli companies raise their first institutional round later in their life. A typical Israeli seed company already has a product, early customers and sometimes revenue. The round carrying the "seed" label pays for go-to-market and is sized to match. A US company at the same label is often pre-product and raising to fund the build.

Israeli companies raise their first institutional round later, so a seed company there is usually further along.

That difference has structural causes. Israeli founders come out of the army and university with years of applied technical work behind them, often with a co-founding team that has already built together, so the product phase is short and self-funded or angel-funded. The home market is small, so the company sells abroad from its first customer, and that pushes go-to-market spend into the seed round. And the pool of Israeli seed investors is thinner than the US pool. A company that reaches the seed stage has already cleared a higher bar.

Valuation is a separate question, and it's where the thesis lives. The argument is that Israeli seed rounds price below US rounds for a company of comparable maturity: the local investor base is smaller, US coastal funds rarely lead Israeli seed rounds, and founders benchmark against local comparables. That's consistent with what practitioners on both sides report. It isn't a published series yet, though, and this guide won't claim a number it can't cite.

Where the gap is narrowing

The gap is narrowing at the top of the market and at the pre-seed end. IVC records early-round medians at historic highs in the first half of 2026, driven by bigger rounds into fewer companies and by a surge in defense, space and quantum funding. Startup Nation Central reports pre-seed round sizes and valuation caps rising year over year.

Top-decile Israeli rounds now price against US comparables. The median company still raises later, on local terms.

Israeli founders raising in cyber, defense and AI infrastructure in 2026 are increasingly priced against US comparables. Two forces push the other way, though. The market's own concentration means the median company outside the top decile is raising less, later, on local terms, and that's exactly the company a seed fund with relationships can reach. And pre-seed has stayed stagnant: IVC's median has been flat at $0.2 million since 2023 and the pool of individual backers is contracting, so the entry point before the institutional seed is, if anything, cheaper than it was.

In practice, "buy in Tel Aviv" is a claim about access to the median company at the seed stage. There's no market-wide discount that anyone can capture just by wiring money into the hot rounds.

What it means for entry price

A fund's entry price is the valuation its first check goes in at. The spread is that valuation against the US valuation of a company with the same product, team and traction. On round size alone, an Israeli seed company is later and more de-risked than the US label implies, so the right US comparable is often a Series A.

On round size alone, the right US comparable for an Israeli seed company is often a Series A.

Say the valuation evidence, once published, shows Israeli seed rounds pricing at or near US seed valuations while the companies look like US Series A companies. Then the spread is the difference between those two US price points, captured at entry. If it shows Israeli rounds priced at US Series A levels, the spread is smaller than the thesis assumes, and the fund's edge comes from selection and access more than price. Olivent's position is that the first reading holds for the median company outside the top decile. The data note is where that claim gets tested against numbers as they're published.

Either way, a seed fund's arithmetic is set by the outliers. The exit side of the spread, US acquirers and US public markets, is where Israeli-founded companies have historically realised value. The Fund I terms and the thesis describe how Olivent is built around that.